What is the role of QTc prolongation assessment in new drugs development phase I oncology trials?
Giuseppe Curigliano(European Institute of Oncology), Filippo de Braud(University of Milan), Cristina Noberasco(European Institute of Oncology), Carlo Putzu(Institute of Oncology Research), Gianluca Spitaleri(Institute of Oncology Research), Alessandra Milani(Institute of Oncology Research), Tomasso De Pas(Institute of Oncology Research), C. Sessa(Hospital Clínico Universitario de Valencia), N. Colombo(Mylan (Switzerland)), Carlo M. Cipolla(European Institute of Oncology)
Cited by 5
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k